CIBC Asset Administration Inc boosted its stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 7.9% through the third quarter, based on the corporate in its most up-to-date submitting with the Securities & Trade Fee. The institutional investor owned 33,973 shares of the medical tools supplier’s inventory after buying a further 2,483 shares through the quarter. CIBC Asset Administration Inc’s holdings in Hologic had been price $2,767,000 as of its most up-to-date SEC submitting.
Different institutional traders have additionally lately made modifications to their positions within the firm. Wolff Wiese Magana LLC bought a brand new place in shares of Hologic within the third quarter valued at $25,000. Innealta Capital LLC bought a brand new place in shares of Hologic through the second quarter valued at roughly $25,000. iA World Asset Administration Inc. bought a brand new place in shares of Hologic through the first quarter valued at roughly $37,000. Sunbelt Securities Inc. bought a brand new stake in shares of Hologic within the second quarter price roughly $37,000. Lastly, Cromwell Holdings LLC boosted its holdings in Hologic by 330.2% through the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical tools supplier’s inventory valued at $44,000 after buying a further 416 shares through the interval. Hedge funds and different institutional traders personal 94.73% of the corporate’s inventory.
Analysts Set New Value Targets
HOLX has been the topic of a number of analysis studies. Raymond James boosted their worth goal on shares of Hologic from $93.00 to $95.00 and gave the corporate an “outperform” score in a analysis report on Tuesday, November fifth. Citigroup lowered shares of Hologic from a “purchase” score to a “impartial” score and lowered their worth goal for the inventory from $95.00 to $85.00 in a analysis notice on Tuesday, October 1st. Stephens reiterated an “obese” score and set a $92.00 worth goal on shares of Hologic in a analysis notice on Tuesday, July thirtieth. JPMorgan Chase & Co. elevated their goal worth on Hologic from $92.00 to $94.00 and gave the corporate an “obese” score in a analysis report on Tuesday, November fifth. Lastly, UBS Group boosted their worth goal on Hologic from $84.00 to $90.00 and gave the inventory a “impartial” score in a analysis report on Tuesday, November fifth. 4 analysis analysts have rated the inventory with a maintain score and 9 have issued a purchase score to the corporate’s inventory. Based mostly on information from MarketBeat.com, the corporate presently has a consensus score of “Average Purchase” and a consensus worth goal of $89.91.
View Our Newest Evaluation on HOLX
Hologic Value Efficiency
HOLX inventory opened at $78.79 on Tuesday. The corporate has a debt-to-equity ratio of 0.49, a present ratio of three.69 and a fast ratio of three.03. The enterprise has a 50 day easy transferring common of $80.63 and a 200-day easy transferring common of $78.28. The agency has a market capitalization of $18.30 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of two.48 and a beta of 0.98. Hologic, Inc. has a 1 yr low of $67.59 and a 1 yr excessive of $84.67.
Hologic (NASDAQ:HOLX – Get Free Report) final introduced its quarterly earnings outcomes on Monday, November 4th. The medical tools supplier reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a web margin of 19.59% and a return on fairness of 19.79%. The enterprise had income of $987.90 million through the quarter, in comparison with the consensus estimate of $978.25 million. Throughout the identical quarter final yr, the agency earned $0.89 EPS. The enterprise’s income was up 4.5% in comparison with the identical quarter final yr. Equities analysis analysts anticipate that Hologic, Inc. will put up 4.27 earnings per share for the present fiscal yr.
About Hologic
Hologic, Inc develops, manufactures, and provides diagnostics merchandise, medical imaging techniques, and surgical merchandise for girls’s well being by way of early detection and therapy. The corporate operates by way of 4 segments: Diagnostics, Breast Well being, GYN Surgical, and Skeletal Well being. It supplies Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the analysis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology purposes; and Fast Fetal Fibronectin Take a look at that assists physicians in assessing the danger of pre-term start.
Featured Articles
Obtain Information & Rankings for Hologic Every day – Enter your e-mail tackle under to obtain a concise every day abstract of the newest information and analysts’ rankings for Hologic and associated firms with MarketBeat.com’s FREE every day e-mail e-newsletter.
